702 related articles for article (PubMed ID: 14562125)
1. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Beillard E; Pallisgaard N; van der Velden VH; Bi W; Dee R; van der Schoot E; Delabesse E; Macintyre E; Gottardi E; Saglio G; Watzinger F; Lion T; van Dongen JJ; Hokland P; Gabert J
Leukemia; 2003 Dec; 17(12):2474-86. PubMed ID: 14562124
[TBL] [Abstract][Full Text] [Related]
3. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
4. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
[TBL] [Abstract][Full Text] [Related]
5. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
[TBL] [Abstract][Full Text] [Related]
6. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
7. Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.
Yamada MF; Fujiwara T; Ishikawa I; Kohata K; Katoh C; Miyamura K; Harigae H
Tohoku J Exp Med; 2008 Feb; 214(2):97-104. PubMed ID: 18285666
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
Prezeau N; Silvy M; Gabert J; Picard C
Leuk Res; 2006 May; 30(5):569-74. PubMed ID: 16209886
[TBL] [Abstract][Full Text] [Related]
9. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
10. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
[TBL] [Abstract][Full Text] [Related]
11. Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet.
Østergaard M; Nyvold CG; Jovanovic JV; Andersen MT; Kairisto V; Morgan YG; Tobal K; Pallisgaard N; Ozbek U; Pfeifer H; Schnittger S; Grubach L; Larsen JK; Grimwade D; Hokland P
Leukemia; 2011 Jul; 25(7):1168-73. PubMed ID: 21494256
[TBL] [Abstract][Full Text] [Related]
12. [Expression of PML-RAR alpha fusion transcripts detection by using RQ-PCR].
Han LX; Lin J; Qian J; Wang YL; Qian Z; Yang XF; Sheng XJ; Yao DM
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):753-6. PubMed ID: 19176013
[TBL] [Abstract][Full Text] [Related]
13. Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.
Zhu HH; Liu YR; Qin YZ; Jiang B; Shan FX; Wu SL; Yang PD; Zhao J; Lu DP
Chin Med J (Engl); 2007 Oct; 120(20):1803-8. PubMed ID: 18028775
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
[TBL] [Abstract][Full Text] [Related]
15. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
16. A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached.
Hochhaus A
Leukemia; 2003 Dec; 17(12):2383-4. PubMed ID: 14562123
[No Abstract] [Full Text] [Related]
17. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
20. Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13).
Fujiki A; Imamura T; Furutani A; Hatano W; Asai D; Hirashima Y; Miyachi M; Tamura S; Tsuchiya K; Iehara T; Ishida H; Yoshihara T; Hosoi H
J Pediatr Hematol Oncol; 2012 Jul; 34(5):402-5. PubMed ID: 22278196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]